International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.

Jason Gotlib, Animesh D Pardanani, Cem Akin, Andreas Reiter, Tracy George, Olivier Hermine, Hanneke Kluin-Nelemans, Karin Hartmann, Wolfgang R. Sperr, Knut Brockow, Lawrence B. Schwartz, Alberto Orfao, Daniel J. Deangelo, Michel Arock, Karl Sotlar, Hans Peter Horny, Dean D. Metcalfe, Luis Escribano, Srdan Verstovsek, Ayalew TefferiPeter Valent

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Systemic mastocytosis (SM) is characterized by accumulation of neoplastic mast cells and is classified into indolent and aggressive forms. The latter include aggressive SM (ASM), mast cell leukemia (MCL), and SM associated with a myeloid neoplasm wherein 1 or both disease compartments exhibit advanced features. These variants, henceforth collectively referred to as advanced SM for the purposes of this report, are typically characterized by organ damage and shortened survival duration. In contrast to indolent SM, in which symptoms are usually managed by noncytotoxic antimediator therapy, cytoreduction is usually necessary for disease control in advanced SM. Unfortunately, current drug treatment of these patients rarely results in complete clinical and histopathologic remissions or improved survival time. Previously defined response criteria were adapted to the heterogeneous presentations of advanced SM and the limited effects of available drugs. However, recent advances in understanding the molecular pathogenesis of SM and the corresponding prospect in targeted therapy make it a priority to modify these criteria. Our current study is the product of an international group of experts and summarizes the challenges in accomplishing this task and forwards a new proposal for response criteria, which builds on prior proposals and should facilitate response evaluation in clinical trials.

Original languageEnglish (US)
Pages (from-to)2393-2401
Number of pages9
JournalBlood
Volume121
Issue number13
DOIs
StatePublished - Mar 28 2013

Fingerprint

Systemic Mastocytosis
Disease control
Mastocytosis
Drug therapy
Mental Competency
Consensus
Research
Pharmaceutical Preparations
Neoplasms
Therapeutics
Mast-Cell Leukemia
Survival
Mast Cells
Clinical Trials

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. / Gotlib, Jason; Pardanani, Animesh D; Akin, Cem; Reiter, Andreas; George, Tracy; Hermine, Olivier; Kluin-Nelemans, Hanneke; Hartmann, Karin; Sperr, Wolfgang R.; Brockow, Knut; Schwartz, Lawrence B.; Orfao, Alberto; Deangelo, Daniel J.; Arock, Michel; Sotlar, Karl; Horny, Hans Peter; Metcalfe, Dean D.; Escribano, Luis; Verstovsek, Srdan; Tefferi, Ayalew; Valent, Peter.

In: Blood, Vol. 121, No. 13, 28.03.2013, p. 2393-2401.

Research output: Contribution to journalArticle

Gotlib, J, Pardanani, AD, Akin, C, Reiter, A, George, T, Hermine, O, Kluin-Nelemans, H, Hartmann, K, Sperr, WR, Brockow, K, Schwartz, LB, Orfao, A, Deangelo, DJ, Arock, M, Sotlar, K, Horny, HP, Metcalfe, DD, Escribano, L, Verstovsek, S, Tefferi, A & Valent, P 2013, 'International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.', Blood, vol. 121, no. 13, pp. 2393-2401. https://doi.org/10.1182/blood-2012-09-458521
Gotlib, Jason ; Pardanani, Animesh D ; Akin, Cem ; Reiter, Andreas ; George, Tracy ; Hermine, Olivier ; Kluin-Nelemans, Hanneke ; Hartmann, Karin ; Sperr, Wolfgang R. ; Brockow, Knut ; Schwartz, Lawrence B. ; Orfao, Alberto ; Deangelo, Daniel J. ; Arock, Michel ; Sotlar, Karl ; Horny, Hans Peter ; Metcalfe, Dean D. ; Escribano, Luis ; Verstovsek, Srdan ; Tefferi, Ayalew ; Valent, Peter. / International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. In: Blood. 2013 ; Vol. 121, No. 13. pp. 2393-2401.
@article{1bb4768843084ece950ab5c74f352267,
title = "International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.",
abstract = "Systemic mastocytosis (SM) is characterized by accumulation of neoplastic mast cells and is classified into indolent and aggressive forms. The latter include aggressive SM (ASM), mast cell leukemia (MCL), and SM associated with a myeloid neoplasm wherein 1 or both disease compartments exhibit advanced features. These variants, henceforth collectively referred to as advanced SM for the purposes of this report, are typically characterized by organ damage and shortened survival duration. In contrast to indolent SM, in which symptoms are usually managed by noncytotoxic antimediator therapy, cytoreduction is usually necessary for disease control in advanced SM. Unfortunately, current drug treatment of these patients rarely results in complete clinical and histopathologic remissions or improved survival time. Previously defined response criteria were adapted to the heterogeneous presentations of advanced SM and the limited effects of available drugs. However, recent advances in understanding the molecular pathogenesis of SM and the corresponding prospect in targeted therapy make it a priority to modify these criteria. Our current study is the product of an international group of experts and summarizes the challenges in accomplishing this task and forwards a new proposal for response criteria, which builds on prior proposals and should facilitate response evaluation in clinical trials.",
author = "Jason Gotlib and Pardanani, {Animesh D} and Cem Akin and Andreas Reiter and Tracy George and Olivier Hermine and Hanneke Kluin-Nelemans and Karin Hartmann and Sperr, {Wolfgang R.} and Knut Brockow and Schwartz, {Lawrence B.} and Alberto Orfao and Deangelo, {Daniel J.} and Michel Arock and Karl Sotlar and Horny, {Hans Peter} and Metcalfe, {Dean D.} and Luis Escribano and Srdan Verstovsek and Ayalew Tefferi and Peter Valent",
year = "2013",
month = "3",
day = "28",
doi = "10.1182/blood-2012-09-458521",
language = "English (US)",
volume = "121",
pages = "2393--2401",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.

AU - Gotlib, Jason

AU - Pardanani, Animesh D

AU - Akin, Cem

AU - Reiter, Andreas

AU - George, Tracy

AU - Hermine, Olivier

AU - Kluin-Nelemans, Hanneke

AU - Hartmann, Karin

AU - Sperr, Wolfgang R.

AU - Brockow, Knut

AU - Schwartz, Lawrence B.

AU - Orfao, Alberto

AU - Deangelo, Daniel J.

AU - Arock, Michel

AU - Sotlar, Karl

AU - Horny, Hans Peter

AU - Metcalfe, Dean D.

AU - Escribano, Luis

AU - Verstovsek, Srdan

AU - Tefferi, Ayalew

AU - Valent, Peter

PY - 2013/3/28

Y1 - 2013/3/28

N2 - Systemic mastocytosis (SM) is characterized by accumulation of neoplastic mast cells and is classified into indolent and aggressive forms. The latter include aggressive SM (ASM), mast cell leukemia (MCL), and SM associated with a myeloid neoplasm wherein 1 or both disease compartments exhibit advanced features. These variants, henceforth collectively referred to as advanced SM for the purposes of this report, are typically characterized by organ damage and shortened survival duration. In contrast to indolent SM, in which symptoms are usually managed by noncytotoxic antimediator therapy, cytoreduction is usually necessary for disease control in advanced SM. Unfortunately, current drug treatment of these patients rarely results in complete clinical and histopathologic remissions or improved survival time. Previously defined response criteria were adapted to the heterogeneous presentations of advanced SM and the limited effects of available drugs. However, recent advances in understanding the molecular pathogenesis of SM and the corresponding prospect in targeted therapy make it a priority to modify these criteria. Our current study is the product of an international group of experts and summarizes the challenges in accomplishing this task and forwards a new proposal for response criteria, which builds on prior proposals and should facilitate response evaluation in clinical trials.

AB - Systemic mastocytosis (SM) is characterized by accumulation of neoplastic mast cells and is classified into indolent and aggressive forms. The latter include aggressive SM (ASM), mast cell leukemia (MCL), and SM associated with a myeloid neoplasm wherein 1 or both disease compartments exhibit advanced features. These variants, henceforth collectively referred to as advanced SM for the purposes of this report, are typically characterized by organ damage and shortened survival duration. In contrast to indolent SM, in which symptoms are usually managed by noncytotoxic antimediator therapy, cytoreduction is usually necessary for disease control in advanced SM. Unfortunately, current drug treatment of these patients rarely results in complete clinical and histopathologic remissions or improved survival time. Previously defined response criteria were adapted to the heterogeneous presentations of advanced SM and the limited effects of available drugs. However, recent advances in understanding the molecular pathogenesis of SM and the corresponding prospect in targeted therapy make it a priority to modify these criteria. Our current study is the product of an international group of experts and summarizes the challenges in accomplishing this task and forwards a new proposal for response criteria, which builds on prior proposals and should facilitate response evaluation in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84878423607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878423607&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-09-458521

DO - 10.1182/blood-2012-09-458521

M3 - Article

C2 - 23325841

AN - SCOPUS:84878423607

VL - 121

SP - 2393

EP - 2401

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -